Results 211 to 220 of about 85,599,609 (253)
ABSTRACT The target‐engagement predictor, implemented within the InSilicoTrials cloud‐based, AI‐powered platform for model‐informed drug discovery and development, enables early exploration of time‐dependent pharmacological responses. Predictions can be generated using inputs ranging from molecular structure to in vitro, animal, and clinical data ...
Niccolò Totis +16 more
wiley +1 more source
Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study. [PDF]
Koto R +4 more
europepmc +1 more source
Dysglycaemia and Autonomic Dysfunction: The Diabetes Prevention Program Outcomes Study
ABSTRACT Aim Limited data on the link between various measures of glycemia and metabolism and autonomic dysfunction exist. We assessed the association of fasting plasma glucose [FPG], glycated haemoglobin [HbA1C], fasting insulin, and HOMA‐IR and cardiac autonomic function measures separately for men and women in the Diabetes Prevention Program ...
Justin B. Echouffo‐Tcheugui +12 more
wiley +1 more source
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du +6 more
wiley +1 more source
PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes. [PDF]
Penaforte-Saboia JG +10 more
europepmc +1 more source
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. [PDF]
Elbarbary NS +4 more
europepmc +1 more source
ABSTRACT Aims Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with
Masaya Koshizaka +7 more
wiley +1 more source
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder +13 more
wiley +1 more source
ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro +5 more
wiley +1 more source

